In addition, under the terms of the new agreement Novartis has been granted additional flexibility in ordering of GMP batches across Oxford Biomedica's multiple GMP facilities but will no longer have a minimum order commitment.

This is expected to result in a mid-single digit GBP million reduction in previously guided FY21 revenues. The Group continues to work on multiple CAR-T programs with Novartis, including Kymriah, as well as a broad number of development opportunities on which the Group earns manufacturing revenues, process development fees and royalties on net sales.

John Dawson, Chief Executive Officer of Oxford Biomedica, said: 'This news today is an example of Oxford Biomedica seeking to adapt to customer needs over time, our strength as a long-term partner and our goal to unlock value and build scale across the Group.

'We have enjoyed a strategic partnership with Novartis since 2014 and are excited to announce this updated supply agreement which provides both companies with greater flexibility in GMP supply of vector for Kymriah and other pipeline products and allows us to react to the rapidly growing dynamics of the commercial CAR-T sector.

'In return, we are very pleased to have regained the ability to license our LentiVector platform across all CAR-T targets, maximising our ability to serve a larger proportion of the growing market for lentiviral vectors.'

Contact:

Tel: +44 (0)1865 783 000

Email: ir@oxb.com

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the 'Group') have built a sector leading lentiviral vector delivery platform (LentiVector), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, CNS disorders and liver diseases. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics and Boehringer Ingelheim, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the Group has signed a 3-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people.

(C) 2021 Electronic News Publishing, source ENP Newswire